
|Articles|August 31, 2011
Novel Cancer-Targeting Virus Therapy Shows Efficacy in Early-Stage Trial
Author(s)Anna Azvolinsky
Scientists at Jennerex, Inc. in San Francisco, and collaborators from University of Pennsylvania and the University of Ottawa in Canada have just engineered a poxvirus, JX-594, to selectively replicate in tumor cells that have an activated EGFR/ Ras pathway, but not in normal tissue.
Advertisement
Array
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
Clinical Implications Remain After Dasatinib CRL in CML/ALL
5


















































































